To account for patents, you capitalize the qualifying cost on the balance sheet as an intangible asset, amortize that cost to expense over the shorter of the patent’s legal life or its useful economic life, and write it down if a specific event indicates the carrying value is no longer recoverable. The legal life of a utility patent runs 20 years from the filing date,1United States Patent and Trademark Office. MPEP 2701 – Patent Term but the accounting life is usually shorter because technology moves faster than legal clocks.
What Goes on the Balance Sheet
The first decision is what to capitalize and what to expense immediately. That turns entirely on whether you built the patent in-house or bought it.
Internally Developed Patents
Under US GAAP, nearly all spending during the research and development phase must be expensed in the period it occurs. ASC 730 requires R&D costs to be charged to expense as incurred, on the theory that success is too uncertain to justify recording an asset before you actually have one.2Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive Scientist salaries, laboratory costs, prototype materials, and failed experiments all flow straight to the income statement.
Only a narrow set of costs incurred after the patent becomes legally viable can be capitalized. These are almost exclusively the direct legal and filing costs needed to secure the patent itself: attorney fees for drafting and prosecuting the application, and the government filing and registration fees paid to the USPTO. Together, these capitalizable costs often represent a small fraction of the total money spent bringing the invention into existence, which is why internally developed patents tend to appear on balance sheets at surprisingly low values.
Costs of successfully defending a patent against infringement can also be added to the asset’s carrying value, but only when the defense succeeds and demonstrably increases the patent’s economic value. If the defense fails, those legal costs hit the income statement as a current-period expense.
Purchased Patents
Buying a patent from a third party is simpler. The entire purchase price is capitalized, along with any costs necessary to complete the transaction and prepare the asset for use, such as appraisal fees, broker commissions, and transfer taxes. The result is a capitalized cost basis that reflects the full economic sacrifice required to obtain the asset.
When a patent is acquired as part of a business combination, the company allocates the total acquisition price across all identifiable assets and liabilities at their fair values. The patent receives its own fair value allocation, which becomes its capitalized cost basis going forward. That fair value drives all subsequent amortization and impairment calculations, so getting it right matters.
Amortizing the Cost Over the Patent’s Useful Life
Once the patent is on the books, its capitalized cost is systematically allocated to expense over the period it generates economic value. The mechanics mirror depreciation for physical assets.
The amortization period is the shorter of the legal life or the estimated economic life. In fast-moving technology sectors, a patent’s economic usefulness might last five to seven years before the underlying invention is leapfrogged. Management makes the call, weighing the rate of technological change in the industry, competitive dynamics, expected demand shifts, and the stability of the regulatory environment.
Straight-line amortization is the default. Divide the capitalized cost by the estimated useful life in years and that’s your annual expense. A patent capitalized at $50,000 with an estimated useful life of 10 years generates $5,000 of amortization expense each year. Other patterns, such as units-of-production or accelerated methods, are permitted only if they more accurately reflect how the patent’s economic benefits are actually consumed. Most companies stay with straight-line because justifying an alternative requires significant evidence.
If circumstances change and the remaining useful life needs to be revised, the adjustment is prospective. The remaining carrying value gets spread over the new, shorter remaining life. There is no restating prior periods.
Testing for Impairment
Amortization handles the expected, gradual decline in a patent’s value. Impairment testing addresses the unexpected: a competitor launches a superior product, an adverse court ruling narrows the patent’s scope, or a key licensee cancels. Under ASC 360-10, the test for finite-lived assets is triggered by events rather than performed on a fixed calendar.
Step one compares the patent’s carrying amount to the sum of undiscounted future cash flows expected from continued use and eventual disposal. If those undiscounted cash flows exceed the carrying amount, the patent passes and no impairment is recorded. This is intentionally a low bar, a screen that avoids the cost of a full fair value analysis unless clearly necessary.
If the patent fails step one, you move to fair value. The impairment loss equals the amount by which carrying value exceeds fair value. Fair value is typically determined through a discounted cash flow analysis, with projected cash flows reduced to present value using a discount rate that accounts for the time value of money and the specific risks associated with the patent. The patent is written down to fair value and the loss hits the income statement immediately.
One rule surprises people: US GAAP does not permit reversing a previously recognized impairment loss, even if the patent’s value later recovers. The new lower amount becomes the asset’s cost basis going forward, and the remaining balance is amortized over the remaining useful life. It’s a permanent, one-way adjustment.
Maintenance Fees and Abandonment
Keeping a patent in force requires periodic maintenance fee payments to the USPTO at 3.5, 7.5, and 11.5 years after grant. Under the current fee schedule, the standard amounts are $2,150 at the 3.5-year mark, $4,040 at 7.5 years, and $8,280 at 11.5 years, with reduced rates for small and micro entities.3USPTO – United States Patent and Trademark Office. USPTO Fee Schedule
Maintenance fees are expensed as incurred rather than capitalized. They preserve the existing legal right without creating new economic value or extending the useful life beyond what was already estimated.
When a company decides a patent is no longer worth maintaining, it stops paying and the patent lapses. Under ASC 360-10, a decision to abandon a patent before the end of its previously estimated useful life is an indicator of impairment. Test for recoverability, and if the patent fails, write the carrying value down to fair value, which for an abandoned patent is typically zero or close to it. The remaining net book value is recognized as a loss on the income statement.
Recognizing Royalty Revenue From Licensing
If you license patents to third parties in exchange for royalties, ASC 606 applies a specific exception. Sales-based and usage-based royalties tied to intellectual property licenses are recognized only when the later of two events occurs: the licensee’s actual sale or usage happens, or your performance obligation under the license is satisfied.
You generally cannot estimate and accrue royalty revenue in advance. If a licensee owes $2 per unit sold, the licensor recognizes revenue as units are actually sold, not based on forecasted volumes. The exception applies when the royalty relates solely to a license of intellectual property, or when the license is the predominant item the royalty compensates. If the license is bundled with other goods or services and isn’t the predominant component, the general variable consideration rules apply instead, which may allow earlier recognition based on estimates.
Book Treatment vs. Tax Treatment
Patent accounting for financial reporting and patent accounting for tax follow different rules, and the gap creates deferred tax items you need to track.
A patent acquired from a third party qualifies as a Section 197 intangible under the Internal Revenue Code, which means it must be amortized over a fixed 15-year period for tax purposes, regardless of its actual economic or legal life. A 10-year useful life for book and a 15-year life for tax produces a temporary difference and a corresponding deferred tax item on the balance sheet. Self-created patents generally do not qualify as Section 197 intangibles; the statute specifically excludes intangibles created by the taxpayer unless they were created in connection with acquiring a trade or business.4Office of the Law Revision Counsel. 26 USC 197 – Amortization of Goodwill and Certain Other Intangibles
For internally developed patents, the tax treatment of domestic research and experimental expenditures shifted for tax years beginning after December 31, 2024. For 2026, domestic R&E expenditures are again immediately deductible under Section 174A of the Internal Revenue Code.5Office of the Law Revision Counsel. 26 U.S. Code 174A – Domestic Research or Experimental Expenditures Companies can also elect to capitalize and amortize these costs over a period of at least 60 months. Foreign research expenditures still require amortization over 15 years.6Internal Revenue Service. Revenue Procedure 2025-28 The result is that both GAAP and the tax code now treat domestic R&D spending as an immediate expense, eliminating the temporary difference that existed during the 2022–2024 period. Companies that built deferred tax assets tied to that difference need to unwind them.
A Note on IFRS
If you report under International Financial Reporting Standards, two rules differ from US GAAP in ways that materially change the numbers. Under IAS 38, development costs for internally generated intangibles can be capitalized once specific technical and commercial criteria are met, so an internally developed patent can carry meaningful balance sheet value under IFRS while showing almost none under US GAAP. And under IAS 36, a previously recognized impairment loss on a patent must be reversed if the circumstances that caused it have changed, up to what the carrying value would have been without the write-down.7IFRS Foundation. IAS 36 – Impairment of Assets US GAAP flatly prohibits reversal.
Where Patents Land on the Financial Statements
On the balance sheet, patents appear as non-current assets within the intangible assets category. The reported figure is the net book value: original capitalized cost minus accumulated amortization minus any impairment losses. Accumulated amortization functions as a contra-asset account, reducing the gross carrying amount in the same way accumulated depreciation reduces the value of equipment.
The period’s amortization expense appears on the income statement, typically within operating expenses. Any impairment losses are also reported as operating charges in the period they are recognized.
Footnote disclosures carry much of the detail analysts actually use. Companies must disclose the gross carrying amount and accumulated amortization for patents, broken out by remaining amortization period, and state the methods used to determine useful life and calculate amortization. They must also provide a forward-looking estimate of expected amortization expense for each of the next five fiscal years.8Financial Accounting Standards Board (FASB). Summary of Statement No. 142 When an impairment loss is recorded, the footnotes should describe the circumstances that triggered the write-down and the method used to determine fair value.